At a special “chemistry meets biology” seminar on November 28 2024, Pier Vincenzo Piazza (CEO of Aelis Farma) presented the activities of Aelis Farma. The latter has set up its new screening and identification laboratory for new molecules at the IECB.

Main laboratory / L2 lab

Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company behind a new class of drugs, specific inhibitors of CB1 receptor signaling in the endocannabinoid system (CB1-SSi). CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural brain defense mechanism by the team of Dr. Pier Vincenzo Piazza, the Company's CEO, when he was Director of Inserm's Neurocentre Magendie in Bordeaux.

In addition to its 2 clinical-stage drug candidates developed to treat cannabis abuse disorders and cognitive impairment respectively, the company is developing a broad portfolio of new specific inhibitors of CB1 receptor signalling. These could be used to treat a wide range of diseases, including obesity and metabolic disorders, neurodegenerative diseases, ADHD (attention deficit disorder with/without hyperactivity) and PTSD (post-traumatique stress disorder).

Headed by Michelle Glass, an international CB1 expert and professor at the University of Otago (New Zealand), this new laboratory is equipped with state-of-the-art technologies and proprietary screening platforms, enabling us to carry out in-depth research, discovering promising new molecules and identifying their mechanism of action for the treatment of various pathologies.

Welcome to all Aelis Farma members at the IECB !